Condition: Renal Cell Carcinoma (RCC) · Clear Cell Renal Cell Carcinoma (ccRCC) · Sponsor: The Affiliated Hospital of Qingdao University
Study on the sensitivity, specificity, positive predictive value, negative predictive value, and accuracy of 18F-NY104 PET/CT in diagnosing primary, recurrent, and metastatic lesions of renal cell carcinoma; and investigate the effect of oral low-dose CAIX inhibitor (Acetazolamide) on the tissue distribution of 18F-NY104 in renal cell carcinoma patients, particularly in the stomach and kidneys.
This description comes directly from the study's public registry record.
guang Zhen Wang · ＋86-0532-82913318 · wangzhenguang@qde.edu.cn
Always discuss trial participation with your own doctor first.
| The Affiliated Hospital of Qingdao University | Qingdao, Shandong, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06916624